140 related articles for article (PubMed ID: 33975992)
1. Therapeutic drug monitoring of olanzapine: Easy and reliable method for clinical correlation.
Junutula SP; Dubasi SK; Reddy Padide SG; Miryala GK; Koppolu MS; Bandaru Sheshagiri SB; Eggadi V
Indian J Pharmacol; 2021; 53(1):2-5. PubMed ID: 33975992
[TBL] [Abstract][Full Text] [Related]
2. Long-acting olanzapine injection during pregnancy and breastfeeding: a case report.
Manouilenko I; Öhman I; Georgieva J
Arch Womens Ment Health; 2018 Oct; 21(5):587-589. PubMed ID: 29637404
[TBL] [Abstract][Full Text] [Related]
3. Determination of olanzapine for therapeutic drug monitoring in schizophrenia patients by LC/MS method.
Albayrak M; Kadioglu Y; Yaman ME; Senol O; Oral E
Biomed Chromatogr; 2019 Apr; 33(4):e4468. PubMed ID: 30549068
[TBL] [Abstract][Full Text] [Related]
4. Generic Olanzapine Substitution in Patients With Schizophrenia: Assessment of Serum Concentrations and Therapeutic Response After Switching.
Italiano D; Bruno A; Santoro V; Lanza G; Muscatello MR; Zoccali R; Spina E
Ther Drug Monit; 2015 Dec; 37(6):827-30. PubMed ID: 25830930
[TBL] [Abstract][Full Text] [Related]
5. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia.
Dellva MA; Tran P; Tollefson GD; Wentley AL; Beasley CM
Psychiatr Serv; 1997 Dec; 48(12):1571-7. PubMed ID: 9406266
[TBL] [Abstract][Full Text] [Related]
6. What to Do About Missed Doses? A Retrospective Study of Olanzapine in the Elderly.
Xiao T; Wang Z; Li G; Huang S; Zhu X; Liu S; Li X; Hu J; Shang D; Wen Y
Drug Des Devel Ther; 2021; 15():3411-3423. PubMed ID: 34376974
[TBL] [Abstract][Full Text] [Related]
7. Development of a population pharmacokinetic model of olanzapine for Chinese health volunteers and patients with schizophrenia.
Li A; Ji S; Yue W; Yan H; Dong F; Ruan C; Li W; Lu W; Zhang D; Wang C
BMJ Open; 2018 Aug; 8(8):e020070. PubMed ID: 30121590
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Drug Monitoring of Olanzapine and Cytochrome P450 Genotyping in Nonsmoking Subjects.
Miroshnichenko II; Pozhidaev IV; Ivanova SA; Baymeeva NV
Ther Drug Monit; 2020 Apr; 42(2):325-329. PubMed ID: 31425442
[TBL] [Abstract][Full Text] [Related]
9. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
[TBL] [Abstract][Full Text] [Related]
10. A Retrospective Analysis of Steady-State Olanzapine Concentrations in Chinese Patients Using Therapeutic Drug Monitoring: Effects of Valproate and Other Factors.
Deng SH; Wang ZZ; Lu HY; Li L; Hu JQ; Zhu XQ; Xie HS; Chen HZ; Zhang M; Ni XJ; Qiu C; Shang DW; Wen YG
Ther Drug Monit; 2020 Aug; 42(4):636-642. PubMed ID: 32039940
[TBL] [Abstract][Full Text] [Related]
11. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.
Crespo-Facorro B; Pérez-Iglesias R; Ramirez-Bonilla M; Martínez-García O; Llorca J; Luis Vázquez-Barquero J
J Clin Psychiatry; 2006 Oct; 67(10):1511-21. PubMed ID: 17107241
[TBL] [Abstract][Full Text] [Related]
12. The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia.
Hatta K; Takebayashi H; Sudo Y; Katayama S; Kasuya M; Shirai Y; Morikawa F; Nakase R; Nakamura M; Ito S; Kuga H; Nakamura M; Ohnuma T; Usui C; Nakamura H; Hirata T; Sawa Y;
Psychiatry Res; 2013 Dec; 210(2):396-401. PubMed ID: 23919898
[TBL] [Abstract][Full Text] [Related]
13. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.
Breier A; Meehan K; Birkett M; David S; Ferchland I; Sutton V; Taylor CC; Palmer R; Dossenbach M; Kiesler G; Brook S; Wright P
Arch Gen Psychiatry; 2002 May; 59(5):441-8. PubMed ID: 11982448
[TBL] [Abstract][Full Text] [Related]
14. Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia.
Godleski LS; Goldsmith LJ; Vieweg WV; Zettwoch NC; Stikovac DM; Lewis SJ
J Clin Psychiatry; 2003 Feb; 64(2):119-22. PubMed ID: 12633119
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.
Meltzer HY; Bobo WV; Roy A; Jayathilake K; Chen Y; Ertugrul A; Anil Yağcioğlu AE; Small JG
J Clin Psychiatry; 2008 Feb; 69(2):274-85. PubMed ID: 18232726
[TBL] [Abstract][Full Text] [Related]
16. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
Conley RR; Tamminga CA; Bartko JJ; Richardson C; Peszke M; Lingle J; Hegerty J; Love R; Gounaris C; Zaremba S
Am J Psychiatry; 1998 Jul; 155(7):914-20. PubMed ID: 9659857
[TBL] [Abstract][Full Text] [Related]
17. Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial.
Johnsen E; Kroken RA; Løberg EM; Rettenbacher M; Joa I; Larsen TK; Reitan SK; Walla B; Alisauskiene R; Anda LG; Bartz-Johannessen C; Berle JØ; Bjarke J; Fathian F; Hugdahl K; Kjelby E; Sinkeviciute I; Skrede S; Stabell L; Steen VM; Fleischhacker WW
Lancet Psychiatry; 2020 Nov; 7(11):945-954. PubMed ID: 33069317
[TBL] [Abstract][Full Text] [Related]
18. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients.
Bergemann N; Frick A; Parzer P; Kopitz J
Pharmacopsychiatry; 2004 Mar; 37(2):63-8. PubMed ID: 15048613
[TBL] [Abstract][Full Text] [Related]
19. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
20. Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia.
Lu ML; Wu YX; Chen CH; Kuo PT; Chen YH; Lin CH; Wu TH
PLoS One; 2016; 11(2):e0148539. PubMed ID: 26849777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
